ArticleViruses2022
Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases.
Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Immunogenicity of COVID-19 vaccines in patients with cirrhosis: A meta-analysis.Human vaccines & immunotherapeutics · 2024Pooled it
- Safety and Efficacy of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases: A Systematic Review and Meta-Analysis.International journal of public health · 2024Pooled it
- COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis.Clinical and molecular hepatology · 2022Pooled it
- COVID-19 vaccine immunogenicity in Mongolian adults with and without chronic hepatitis.BMC infectious diseases · 2026Article
- Recommended vaccinations for patients with chronic liver diseases.Clinical and experimental hepatology · 2025Review
- Longitudinal Study of SARS-CoV-2 Vaccinations and Infections in Patients with Gastrointestinal Cancer: Stabilizing Immune Responses and Neutralizing Emerging Variants with Variant-Adapted Antigen Exposures.International journal of molecular sciences · 2024Article
- COVID-19 Vaccination in Liver Cirrhosis: Safety and Immune and Clinical Responses.GE Portuguese journal of gastroenterology · 2024Article
- Efficacy, immunogenicity, and safety of COVID-19 vaccines in individuals with liver cirrhosis: a rapid review and meta-analysis.Clinical and experimental vaccine research · 2024Review
- Vaccine Responses in Patients with Liver Cirrhosis: From the Immune System to the Gut Microbiota.Vaccines · 2024Review
- Safety and Immunogenicity After Primary and Booster Inactivated SARS-Cov-2 Vaccination in Patients with Autoimmune Liver Diseases.Journal of clinical and translational hepatology · 2024Article
- Inactivated SARS-CoV-2 booster vaccine enhanced immune responses in patients with chronic liver diseases.Virologica Sinica · 2023Article
- Deficient Immune Response following SARS-CoV-2 Vaccination in Patients with Hepatobiliary Carcinoma: A Forgotten, Vulnerable Group of Patients.Liver cancer · 2023Article
- Impact of COVID-19 in individuals with and without pre-existent digestive disorders with a particular focus on elderly patients.World journal of gastroenterology · 2023Review
- Efficacy of Vaccine Protection Against COVID-19 Virus Infection in Patients with Chronic Liver Diseases.Journal of clinical and translational hepatology · 2023Review
- Humoral Immune Response after COVID-19 mRNA Vaccination in Patients with Liver Cirrhosis: A Prospective Real-Life Single Center Study.Biomedicines · 2023Article
- Vaccination in liver diseases and liver Transplantation: Recommendations, implications and opportunities in the post-covid era.JHEP reports : innovation in hepatology · 2023Review
- Durability of Immune Response after Application of a Third Dose of SARS-CoV-2 Vaccination in Liver Transplant Recipients.Vaccines · 2023Article
- Efficacy, Safety and Immunogenicity of Anti-SARS-CoV-2 Vaccines in Patients with Cirrhosis: A Narrative Review.Vaccines · 2023Review
- Impact of chronic liver disease on SARS-CoV-2 infection outcomes: Roles of stage, etiology and vaccination.World journal of gastroenterology · 2023Review
- Seroconversion and safety of Covid-19 vaccines in pa-tients with chronic liver disease and liver transplant: A systematic review.Qatar medical journal · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The novel mRNA-based vaccines against SARS-CoV-2 display encouraging safety and efficacy profiles. However, there is a paucity of data regarding their immunogenicity and safety in patients with liver diseases (PWLD), especially in those with cirrhosis. We prospectively assessed anti-SARS-CoV-2 S-spike IgG antibodies and neutralizing activity in fully vaccinated PWLD (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.